Updated on 30 January 2015
Around 1, 27,000 people are currently living with liver cirrohosis in the Philippines as per recent estimates
Singapore: Eisai pharmaceuticals recently announced the launch of LIVAMIN oral granules-the treatment for hypoalbuminemia in the Philippines. The drug treats low levels of blood albumin, a disorder commonly found in patients with liver cirrhosis. Around 1, 27,000 people are currently living with liver cirrohosis in the Philippines as per recent estimates.
The cause of such symptoms associated with decompensated hepatic cirrhosis includes malnutrition or metabolic disorder resulting from hypoalbuminemia that occurs as hepatic cirrhosis progresses. LIVAMIN oral granules ameliorates these symptoms and helps patient recovery.
Ajinomoto Pharmaceuticals holds the manufacturing and marketing authorization rights to LIVAMIN Oral Granules. Eisai obtained the exclusive marketing rights to distribute the product in the Philippines, Hong Kong, China and Macao from Ajinomoto Pharmaceuticals. Clinical trials to obtain rights for distributing the product in China are underway.